Arsenal Biosciences

Arsenal Biosciences, Inc. (ArsenalBio) is a clinical-stage cell therapy company developing programmable T-cell therapies. Its current focus includes next-generation in vivo T-cell therapies for chronic diseases, including cancer and autoimmune disease. The company’s stated purpose is to defeat cancer and develop medicines intended to improve patients’ lives.

ArsenalBio was founded in 2019 and launched publicly in October of that year. Its founding work brought together scientific leaders from academic medical and research institutions. The company is headquartered in South San Francisco, California.

The company applies a programmable, computationally driven approach to engineering T cells. Its publicly described capabilities include CRISPR-based genome engineering, synthetic biology, target identification, and machine learning. ArsenalBio says its proprietary biology toolkit is intended to reprogram T cells and support therapeutic designs with multiple functions.

In its earlier public development program, ArsenalBio described a pipeline of engineered autologous T-cell therapies for solid tumors, with research and clinical programs spanning cancers including ovarian and kidney cancer. The company has also described collaborations to advance T-cell therapies for solid tumors. Its September 2024 financing announcement said proceeds would support development of its programs and expansion of manufacturing capabilities.

In 2026, ArsenalBio announced a strategic focus on in vivo CAR T programs, building on its investments in T-cell biology, synthetic biology, computation, and cell engineering. The company says this direction is intended to address a broader range of diseases and to explore opportunities such as easier manufacturing and lower required doses. These are development goals, not established clinical outcomes.

ArsenalBio’s stated ambitions include improving the activity and safety of cell therapies, addressing the complexity of solid tumors, reducing provider or stakeholder costs, and expanding patient access. The company describes its approach as integrated across technology, biological sciences, clinical work, and manufacturing; its public materials emphasize coordinated, multidisciplinary teams and prioritizing shared team outcomes.

The company’s website presents ArsenalBio as a biotechnology organization working to develop potential cell therapies, rather than as a provider of marketed treatments. Its public-facing purpose is summarized in the phrase “Engineering Hope,” and its stated mission is to develop medicines for people facing cancer and other chronic diseases.